DYAX ANNOUNCES POSITIVE RESULTS FROM TRIAL OF SUBCUTANEOUS DX-88

A A

Dyax has reported positive final data from its Phase I trial, demonstrating that DX-88 was safe and well-tolerated in normal volunteers when administered subcutaneously. DX-88 is being developed in a joint venture with Genzyme for the treatment of hereditary angioedema (HAE), a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of severe peripheral, abdominal and/or laryngeal pain and swelling.

Based on the pharmacokinetic and safety profiles observed in the trial, Dyax has now converted all clinical sites in the ongoing EDEMA2 trial from intravenous (IV) dosing to the more easily administered subcutaneous (SQ) injection of DX-88. This conversion has provided HAE patient experience with SQ DX-88 prior to the initiation of a pivotal Phase III trial planned to start before the end of the year.